Incyte Corporation (NASDAQ:INCY) President Herve Hoppenot sold 70,502 shares of the company’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $119.45, for a total transaction of $8,421,463.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Incyte Corporation (NASDAQ:INCY) opened at 115.05 on Friday. Incyte Corporation has a 12-month low of $83.01 and a 12-month high of $153.15. The company’s market cap is $23.67 billion. The company’s 50-day moving average is $126.44 and its 200-day moving average is $129.92.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The business had revenue of $326.40 million during the quarter, compared to analysts’ expectations of $318.45 million. During the same period in the previous year, the business posted $0.18 EPS. The business’s quarterly revenue was up 32.5% compared to the same quarter last year. Equities research analysts predict that Incyte Corporation will post ($0.82) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Herve Hoppenot Sells 70,502 Shares of Incyte Corporation (INCY) Stock” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/herve-hoppenot-sells-70502-shares-of-incyte-corporation-incy-stock/1579256.html.

A number of large investors have recently modified their holdings of the business. Wetherby Asset Management Inc. lifted its holdings in Incyte Corporation by 1.4% during the second quarter. Wetherby Asset Management Inc. now owns 1,672 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 23 shares in the last quarter. Nordea Investment Management AB lifted its holdings in Incyte Corporation by 0.8% during the second quarter. Nordea Investment Management AB now owns 8,179 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 67 shares in the last quarter. Grandfield & Dodd LLC lifted its holdings in Incyte Corporation by 1.2% during the second quarter. Grandfield & Dodd LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $930,000 after purchasing an additional 85 shares in the last quarter. IFP Advisors Inc lifted its holdings in Incyte Corporation by 9.9% during the second quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 103 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Incyte Corporation by 13.8% during the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 108 shares in the last quarter. 88.91% of the stock is currently owned by institutional investors and hedge funds.

INCY has been the subject of a number of recent analyst reports. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $149.00 price objective on shares of Incyte Corporation in a research report on Thursday, August 31st. BMO Capital Markets reaffirmed an “outperform” rating and issued a $172.00 price objective on shares of Incyte Corporation in a research report on Monday, August 28th. BidaskClub raised shares of Incyte Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Raymond James Financial, Inc. raised shares of Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 price objective for the company in a research report on Monday, September 11th. Finally, Argus reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Incyte Corporation in a research report on Wednesday, September 13th. Eight research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Incyte Corporation currently has a consensus rating of “Buy” and an average price target of $142.16.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.